Physician profile
Fiona Gupta
NPI 1346409547
$1,100,130.21
in general payments reported to CMS, 2019-2025
50 companies · $423K in 2025
The $423K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $62K · 2021: $45K · 2022: $63K · 2023: $158K · 2024: $252K · 2025: $423K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $432K · Consulting Fee: $140K · Honoraria: $124K · Travel and Lodging: $105K · Food and Beverage: $29K · Education: $2,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $432,187.52 |
| Consulting Fee | $140,048.68 |
| Honoraria | $124,394.00 |
| Travel and Lodging | $104,670.95 |
| Food and Beverage | $28,799.50 |
| Education | $2,134.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $435,630.54 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $213,857.76 | 2019-2025 | Gocovri, Apokyn, Apokyn |
| Amneal Pharmaceuticals LLC | $108,978.23 | 2019-2025 | Crexont, Ongentys, Rytary |
| Acadia Pharmaceuticals INC | $106,672.34 | 2019-2025 | Nuplazid |
| Abbott Laboratories | $68,978.60 | 2019-2025 | Infinity, Xience Skypoint |
| Merz Pharmaceuticals, LLC | $37,689.35 | 2022-2025 | Inbrija, Xeomin |
| Kyowa Kirin, INC. | $28,282.35 | 2019-2024 | Nourianz |
| Sunovion Pharmaceuticals INC. | $23,896.51 | 2019-2020 | |
| Abbvie INC. | $19,318.43 | 2019-2025 | |
| Merz North America, INC. | $18,205.45 | 2019-2020 | |
| Acorda Therapeutics, INC | $13,252.28 | 2019-2024 | Inbrija |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $7,300.00 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $4,091.67 | 2019-2025 | |
| Medtronic, INC. | $2,823.87 | 2021-2025 | Percept Pc Brainsense, Sensight |
| Global Kinetics USA Corporation | $1,500.00 | 2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $868.82 | 2024-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $859.63 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Zoll Medical Corporation | $800.00 | 2022-2023 | |
| Pfizer INC. | $734.12 | 2024-2025 | |
| Becton, Dickinson and Company | $445.00 | 2020-2024 | Bd Introsyte |
| Lantheus Medical Imaging, INC. | $400.00 | 2025 | |
| Eisai INC. | $372.99 | 2024-2025 | |
| Boston Scientific Corporation | $370.97 | 2019-2023 | |
| Tg Therapeutics, INC. | $369.32 | 2024-2025 | |
| Ucb, INC. | $357.19 | 2024-2025 | Briviact, Rystiggo, Fintepla |
| Allergan, INC. | $348.26 | 2019-2022 | |
| Harmony Biosciences LLC | $319.97 | 2024-2025 | |
| Axsome Therapeutics, INC. | $311.81 | 2025 | Symbravo |
| Halozyme INC | $287.00 | 2024 | |
| Biogen, INC. | $282.76 | 2024-2025 | Tysabri, Vumerity, Leqembi |
| Argenx US, INC. | $250.96 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Emd Serono, INC. | $250.00 | 2019-2020 | |
| Lilly USA, LLC | $242.84 | 2024-2025 | Kisunla, Emgality, Amyvid |
| Medtronic USA, INC. | $221.61 | 2019-2020 | |
| Dr.Reddy'S Laboratories,INC. | $220.00 | 2023 | |
| Saluda Medical Americas, INC. | $217.59 | 2024 | Evoke |
| Adamas Pharmaceuticals, INC. | $189.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.42 | 2024-2025 | Hyqvia |
| Insightec,INC | $145.51 | 2024 | Exablate |
| Ipsen Biopharmaceuticals, INC | $134.75 | 2024-2025 | Dysport |
| Amgen INC. | $114.16 | 2024-2025 | Uplizna |
| Currax Pharmaceuticals LLC | $65.80 | 2024 | Onzetra Xsail |
| Grifols USA, LLC | $64.23 | 2025 | Gamunex-C |
| Ge Healthcare | $53.97 | 2025 | |
| Octapharma USA, INC. | $46.51 | 2025 | Panzyga |
| Revance Therapeutics, INC. | $40.12 | 2024 | Daxi |
| Globus Medical, INC. | $29.57 | 2025 | Senza |
| Otsuka America Pharmaceutical, INC. | $22.44 | 2024 | Nuedexta |
| Bausch Health US, LLC | $22.06 | 2024 | Wellbutrin, Aplenzin |
| Neurelis, INC. | $21.96 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.